V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10004657 | 10002941 | 1.82 | 75.6 | Neo-adjuvant (N) | 2013-08-04 | 2013-08-15 | Cetuximab + Radiotherapy Load | null | null | 10541078 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004658 | 10002941 | null | null | Palliative (P) | 2017-06-17 | 2017-06-18 | Bevacizumab + Paclitaxel | N | N | 10541078 | NIVOLUMAB |
| 10004659 | 10002941 | 1.56 | 59.3 | Palliative (P) | 2018-07-20 | 2018-08-11 | Cyclophosphamide + Docetaxel | null | null | 10541078 | CISPLATIN + DOXORUBICIN |
| 10004660 | 10002942 | 1.78 | 76.5 | Curative (C) | 2017-07-08 | 2017-07-13 | RIALTO TRIAL | null | N | 10541154 | CYTARABINE |
| 10004661 | 10002943 | null | 75.3 | Palliative (P) | 2018-07-02 | 2018-07-13 | Sorafenib | 02 | N | 10541199 | CHLORAMBUCIL + RITUXIMAB |
| 10004662 | 10002943 | 1.75 | 65.5 | Curative (C) | 2016-01-05 | 2016-01-05 | AML18 PILOT TRIAL | N | N | 10541199 | FLUOROURACIL + MITOMYCIN |
| 10004663 | 10002944 | 1.54 | 51 | Adjuvant (A) | 2016-05-20 | 2016-05-26 | Pazopanib | N | N | 10541244 | NOT MATCHED |
| 10004664 | 10002945 | null | 61.8 | Palliative (P) | 2016-05-05 | 2016-05-05 | MPV (cycle 1-4) | null | N | 10541294 | CYCLOPHOSPHAMIDE + RITUXIMAB |
| 10004665 | 10002945 | null | 83 | Neo-adjuvant (N) | 2018-01-29 | 2018-01-31 | Pazopanib | N | N | 10541294 | IPILIMUMAB + NIVOLUMAB |
| 10004666 | 10002946 | 1.77 | 89 | Curative (C) | 2019-03-24 | 2019-03-25 | Sunitinib | 02 | N | 10541450 | CARBO + FLUOROURACIL |
| 10004667 | 10002946 | 1.67 | 63.9 | Palliative (P) | 2016-07-08 | 2016-07-11 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | N | N | 10541450 | BORTEZOMIB + THALIDOMIDE |
| 10004668 | 10002947 | 1.59 | 60.9 | Palliative (P) | 2018-07-31 | 2018-08-24 | METHOTREXATE HIGH DOSE + RITUXIMAB | N | Y | 10541507 | ERLOTINIB |
| 10004669 | 10002947 | 1.71 | 73 | Palliative (P) | null | 2018-01-21 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN | 02 | N | 10541507 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004670 | 10002948 | 1.7 | 76.5 | Curative (C) | 2016-06-26 | 2016-06-26 | Cisplatin +Fluorouracil (3 wk) | 2 | N | 10541531 | AML18 TRIAL |
| 10004671 | 10006691 | 1.72 | 76.65 | Neo-adjuvant (N) | 2018-03-10 | 2018-03-16 | Cisplatin + Docetaxel +Fluorouracil | N | N | 10541638 | CARBOPLATIN + PACLITAXEL + RT |
| 10004672 | 10006691 | null | null | Palliative (P) | 2017-07-21 | 2017-08-05 | BORTEZOMIB + THALIDOMIDE | 2 | Y | 10541638 | OCTREOTIDE |
| 10004673 | 10002949 | 0 | 73 | Palliative (P) | 2018-05-17 | 2018-06-28 | RUXOLITINIB | N | N | 10541696 | PEMETREXED |
| 10004674 | 10002950 | 1.68 | 51.8 | Palliative (P) | 2018-07-21 | 2018-07-21 | Vemurafenib | Y | N | 10541774 | CAPECITABINE + EPIRUBICIN + OXALIPLATIN |
| 10004675 | 10002951 | null | null | Adjuvant (A) | 2017-11-09 | 2017-11-23 | Mitomycin Intravesical | null | N | 10541780 | MITOMYCIN INTRAVESICULAR |
| 10004676 | 10002952 | 1.73 | 64 | c | 2015-01-06 | 2015-01-10 | STAMPEDE TRIAL | N | N | 10541853 | CARBOPLATIN + RT |
| 10004677 | 10002953 | 155 | 0 | Adjuvant (A) | 2014-05-30 | 2014-05-31 | IPILIMUMAB + NIVOLUMAB | 2 | N | 10541867 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 10004678 | 10002953 | 1.69 | 79 | Curative (C) | 2017-04-17 | 2017-04-20 | STAR TRIAL | null | null | 10541867 | TRASTUZUMAB |
| 10004679 | 10002954 | null | 83 | null | 2016-11-09 | 2016-11-09 | CHLORAMBUCIL + ETOPOSIDE + VINBLASTINE | N | null | 10541907 | PILOT TRIAL |
| 10004680 | 10006693 | 1.77 | 93 | Neo-adjuvant (N) | null | 2015-03-22 | PACE-BOM | N | N | 10541948 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10004681 | 10002955 | 1.65 | null | null | null | 2016-11-10 | Vinorelbine (oral) | Y | N | 10541961 | AML16 TRIAL |
| 10004682 | 10002956 | 1.77 | 79.8 | Adjuvant (A) | 2016-05-03 | 2016-06-26 | BEP 5 Day | N | N | 10542010 | CETUXIMAB + IRINOTECAN + MDG |
| 10004683 | 10002956 | 1.56 | 71.7 | Curative (C) | 2018-07-22 | 2018-07-30 | LOMUSTINE + PROCARBAZINE + VINCRISTINE | 02 | N | 10542010 | CISPLATIN + VINORELBINE + RT |
| 10004684 | 10002956 | null | 75.6 | Curative (C) | null | 2017-11-21 | Pazopanib | N | null | 10542010 | BUSULPHAN |
| 10004685 | 10002956 | 1.68 | 66.9 | Neo-adjuvant (N) | 2018-06-14 | 2018-06-14 | PACE-BOM | N | null | 10542010 | CYCLOPHOSPHAMIDE + LENALIDOMIDE |
| 10004686 | 10002956 | 1.72 | null | Palliative (P) | 2018-09-21 | 2018-09-21 | CISPLATIN + VINORELBINE + RT | null | null | 10542010 | SCOPE 1 TRIAL |
| 10004687 | 10002957 | 0 | 65.8 | Palliative (P) | 2018-06-01 | 2018-06-03 | CAPECITABINE + CARBOPLATIN | N | N | 10542314 | IBRUTINIB |
| 10004688 | 10002958 | 0 | 73.7 | Neo-adjuvant (N) | 2018-11-24 | 2018-12-01 | CHLVPP | 2 | Y | 10542316 | ACTICCA-1 TRIAL |
| 10004689 | 10002958 | 1.58 | 82 | Neo-adjuvant (N) | 2018-11-03 | 2018-11-21 | Mitomycin Intravesical | 01 | N | 10542316 | LENALIDOMIDE |
| 10004690 | 10002958 | 1.53 | 62 | Palliative (P) | 2017-04-21 | 2017-05-25 | DOXORUBICIN | N | N | 10542316 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10004691 | 10002958 | 1.68 | 55.7 | Disease modification (D) | 2018-06-24 | 2018-07-22 | CMF Classical 28 day Oral | N | Y | 10542316 | CAPECITABINE + CISPLATIN + RT |
| 10004692 | 10002959 | null | null | Palliative (P) | 2017-12-30 | 2018-01-06 | Sunitinib | 01 | N | 10542610 | IBRUTINIB |
| 10004693 | 10002959 | 1.63 | 52 | Palliative (P) | 2017-11-08 | 2017-11-08 | Cyclophosphamide + Docetaxel | 2 | N | 10542610 | CHLORAMBUCIL + RITUXIMAB |
| 10004694 | 10002959 | 1.65 | 53 | Palliative (P) | 2015-04-02 | 2015-04-02 | CHLORAMBUCIL + RITUXIMAB | N | N | 10542610 | REMODL TRIAL |
| 10004695 | 10002960 | null | 71.3 | Neo-adjuvant (N) | 2013-04-08 | 2018-10-13 | Ipilimumab | 02 | N | 10542683 | CISPLATIN + DOCETAXEL + FLUOROURACIL |
| 10004696 | 10002961 | null | 115.5 | Curative (C) | 2018-08-15 | 2018-08-15 | OXALIPLATIN | 02 | N | 10542690 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE |
| 10004697 | 10002962 | null | 82 | Adjuvant (A) | 2017-03-31 | 2017-04-22 | Vemurafenib | N | N | 10542714 | BENDAMUSTINE |
| 10004698 | 10002962 | 1.67 | 78 | Palliative (P) | 2017-03-31 | 2017-04-23 | CISPLATIN + FLUOROURACIL | 2 | N | 10542714 | FLUOROURACIL + RT |
| 10004699 | 10002962 | 0 | 76.9 | Palliative (P) | 2014-11-22 | 2014-12-04 | TEMOZOLOMIDE | Y | N | 10542714 | VINORELBINE |
| 10004700 | 10002963 | null | 58.6 | null | 2017-01-28 | 2017-01-29 | Sorafenib | 02 | N | 10542758 | LOMUSTINE |
| 10004701 | 10002964 | null | null | Palliative (P) | 2014-05-03 | 2014-05-13 | Lomustine | null | N | 10542829 | CISPLATIN + VINORELBINE + RT |
| 10004702 | 10002965 | null | 83 | Palliative (P) | 2016-06-01 | 2016-06-01 | Doxorubicin chemoembolisation | N | N | 10542857 | GEFITINIB |
| 10004703 | 10002965 | 1.69 | 115.5 | Neo-adjuvant (N) | null | 2013-09-27 | INCA TRIAL | 02 | N | 10542857 | RUXOLITINIB |
| 10004704 | 10002965 | 0 | 95.2 | Curative (C) | 2018-01-14 | 2018-02-04 | AFATINIB | 02 | N | 10542857 | SORAFENIB |
| 10004705 | 10002965 | 0 | 50.8 | Unknown (U) | 2016-11-04 | 2016-11-05 | TEMOZOLOMIDE | 02 | N | 10542857 | RUXOLITINIB |
| 10004706 | 10002965 | 0 | 81 | Palliative (P) | 2017-02-04 | 2017-02-05 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | N | N | 10542857 | CETUXIMAB |